Clinical Trial Update: Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) [Phase 4]

View source ↗

Summary

This Phase 4 exploratory trial compared PERMIXON 160 mg hard capsules (LipidoSterolic Extract of Serenoa Repens) versus Tamsulosin LP for inflammation biomarker…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• PERMIXON 160 mg Hard Capsule (LipidoSterolic Extract of Serenoa Repens)
• Tamsulosin LP (Tamsulosin)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Benign Prostatic Hyperplasia (BPH) | Phase 4 | Status: COMPLETED